Please provide your email address to receive an email when new articles are posted on . Teprotumumab reduces proptosis by 2 mm or more for most adults with long-standing thyroid eye disease and low ...

Credit: Getty Images. Tepezza is a human insulin-like growth factor-1 receptor inhibitor. Tepezza ® (teprotumumab-trbw) significantly reduced proptosis in adults with chronic thyroid eye disease (TED) ...

Please provide your email address to receive an email when new articles are posted on . A 78-year-old woman was referred to the neuro-ophthalmology service at New England Eye Center for several months ...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new pooled efficacy data from the Phase 2 and 3 clinical trials of TEPEZZA™ (teprotumumab-trbw) showing that the ...

Findings from THRIVE showed treatment with veligrotug led to statistically significant improvements in the signs and symptoms of TED. Topline data were announced from a phase 3 study evaluating ...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 3 clinical trial (OPTIC-J) in Japan evaluating teprotumumab for the ...

A 60-year-old white woman complains of progressive double vision in the left eye that began 8 months ago. She also notes tearing and discharge from the eye and complains of increased bulging of the ...

Researchers from the Schepens Eye Research Institute of Massachusetts Eye and Ear have identified new underlying mechanisms of proptosis, or bulging of the eyes, in patients with acute thyroid eye ...

A 14-year-old otherwise healthy girl developed right eye pain in the periorbital area and proptosis of sudden onset. She was being followed because of mild proptosis. However, the eyelid swelling ...

Acelyrin plans to start a Phase 2b/3 trial of lonigutamab for thyroid eye disease in the second half of 2024. Acelyrin will forego hosting the fiscal year 2023 earnings call and instead announce its ...

Powerful anti-tumor response associated with reduction in proptosis (eye-bulging) and reduced ocular pain Heavily pre-treated patient had failed 7 prior regimens including antibody-drug conjugate ...

-- Teprotumumab is marketed under the brand name TEPEZZA® in the United States-- The primary efficacy endpoint is proptosis response rate at Week 24, measured by the percentage of participants with at ...